A critical issue for all emerging biopharmaceutical companies is their valuation- and how clinical trial results from their assets impact on that. This #IQVIA webinar discusses original research by IQVIA statistically analysing the link between valuation changes for biotech companies and types of clinical trials outcomes announcements. Recommended for a statistically robust, quantitative approach to a key #Biotech business issue.
Join our panel of speakers in this live webinar tomorrow as they discuss how to maximise biopharma valuations, considering investors’ prior expectations, development phase at readout, therapy area, and trial design. Register now to secure your spot. https://bit.ly/3zMCnph #biotech #emergingbiopharma
